Comparison
BPC-157 vs. Bremelanotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Research other
CAS no.
137525-51-0
189691-06-3
Molecular weight
1419.5 g/mol
1025.18 g/mol
Half-life
4 h
2.7 h
Sequence
GEPPPGKPADDAGLVAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
5
of which in humans
0
5
Effects recorded
4
3
Open conflicts
2
0
Documented adverse events
2
2